GleamWall
中文EN

CRBP Corbus Pharmaceuticals Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595097 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.3%
TTM EPS YoY-10.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-131.5%
ROA-100.1%
ROIC (approx.)-160.1%
Asset turnover—

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-20.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$70.09M$32.22M
SG&A expense$15.21M$16.50M
Operating income-$85.31M-$48.72M
Interest expense$0$1.87M
Income tax$0$0
Net income-$78.54M-$40.21M
EBITDA-$85.08M-$48.13M
EPS (basic)-5.90-3.68
EPS (diluted)-5.90-3.68
Weighted avg. shares (diluted)13.32M10.92M
Balance sheet
Cash & equivalents$28.49M$17.20M
Short-term investments$134.78M$131.86M
Current assets$166.95M$152.98M
PP&E, net$159,000$385,000
Total assets$168.19M$155.88M
Current liabilities$20.69M$11.82M
Total liabilities$20.69M$13.45M
Shareholders' equity$147.50M$142.43M
Shares outstanding17.61M12.18M
Cash flow statement
Operating cash flow-$64.49M-$41.79M
Capital expenditure$7,000$0
Free cash flow-$64.50M-$41.79M
Investing cash flow-$1.64M-$121.31M
Financing cash flow$77.43M$166.58M
Depreciation & amortization$233,000$588,000
Stock-based compensation$6.29M$6.14M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.